A clinical study of avacopan in lupus nephritis
Latest Information Update: 12 May 2022
At a glance
- Drugs Avacopan (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions; Therapeutic Use
- 05 May 2022 According to a ChemoCentryx media release, the company expects to receive feedback from the FDA mid-year 2022 regarding the clinical development plan for TAVNEOS in Lupus nephritis.
- 01 Mar 2022 According to a ChemoCentryx media release, the company plans to initiate this study in the second half of 2022, due to pending interaction with regulatory agencies.
- 09 Nov 2021 According to a ChemoCentryx media release, the company plans to initiate this study in mid- 2022.